GEN Exclusives

More »

Point of View

More »
Feb 1, 2011 (Vol. 31, No. 3)

A Golden Opportunity Choked by Red Tape

Widespread Use of Vitamin A Enriched Rice Forestalled by Gratuitous Regulation

  • Golden Rice offers the potential to make contributions to human health and welfare as monumental as any in history. With wide use, it could save hundreds of thousands of lives a year and enhance the quality of life for millions more.

    But one aspect of this shining story is tarnished. Intransigent opposition by antiscience, antitechnology activists—Greenpeace, Friends of the Earth, and a few other groups—has spurred already risk-averse regulators to adopt an overly precautionary approach that has stalled approvals.

    There is absolutely nothing about Golden Rice that should require endless case-by-case reviews and bureaucratic dithering. As the scientific journal Nature editorialized in 1992, a broad scientific consensus holds that “the same physical and biological laws govern the response of organisms modified by modern molecular and cellular methods and those produced by classical methods. ...[Therefore] no conceptual distinction exists between genetic modification of plants and microorganisms by classical methods or by molecular techniques that modify DNA and transfer genes.”

    Putting it another way, government regulation of field research with plants should focus on the traits that may be related to risk—invasiveness, weediness, toxicity, and so forth—rather than on whether one or another technique of genetic manipulation was used.

    In spite of its vast potential to benefit humanity—and negligible likelihood of harm to human health or the environment—Golden Rice remains hung up in regulatory red tape with no end in sight. In a July commentary in Nature, Potrykus pointed out that Golden Rice has been “stalled at the development stages for more than ten years by the working conditions and requirements demanded by regulations.”

    By contrast, plants constructed with less precise techniques such as hybridization or mutagenesis generally are subject to no government scrutiny or requirements (or opposition from activists) at all. And that applies even to the numerous new plant varieties that during the past half century have resulted from “wide crosses,” hybridizations that move genes from one species or genus to another—across what used to be thought of as natural breeding boundaries.

    Pulling no punches, Potrykus holds gratuitous regulation “responsible for the death and blindness of thousands of children and young mothers.” At the very least, the politicians, activists, and regulators who have insisted on, implemented, and maintained those regulations are guilty of what the legal system calls “reckless disregard for life.”

    In an editorial in the journal Science, Nina Fedoroff, an eminent plant geneticist and professor at Pennsylvania State University who recently completed a three-year stint as senior scientific adviser to U.S. Secretary of State, wrote: “A new Green Revolution demands a global commitment to creating a modern agricultural infrastructure everywhere, adequate investment in training and modern laboratory facilities, and progress toward simplified regulatory approaches that are responsive to accumulating evidence of safety. Do we have the will and the wisdom to make it happen?”

    The Golden Rice story makes it clear that the answer is, not yet.


Readers' Comments

Posted 02/02/2011 by peter jockel

i hate to say this , however, if we do not take advantage of this"golden opportunity", others will. i have seen this too often in too many fields. thank you. i have always enjoyed your editorials.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?